IMCR · Immunocore Holdings plc · Earnings Calls, Transcripts & Webcasts
$26.41
-0.22 (-0.83%)
At close · Nov 20
Return incl. dividend (before tax)
Q4 2025 earnings call transcript
Market Cap
$1.36B
Shares
51.68M
Volume · Nov 20
546.2K
Avg daily vol (3M)
449.07K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Immunocore Holdings plc Webcasts
Earnings calls, investor updates, investor days and conferences for Immunocore Holdings plc (IMCR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Immunocore Holdings plc (IMCR) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Immunocore Holdings plc (IMCR) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call
Revenue
$115.93M
▲ 18.3% YoY Diluted EPS
$-0.02
Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Immunocore Holdings plc (IMCR) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Confident tone
KIMTRAK commercial performance
Cutaneous melanoma opportunity
Pipeline expansion and Phase 3 trials
Revenue
$104.48M*
▲ 24.3% YoY Gross margin
97.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-07
Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript
Confident tone
TEBE-AM Phase III in second-line cutaneous melanoma
KIMMTRAK commercial performance and global expansion
U.S. market dynamics and duration of therapy
Revenue
$97.96M
▲ 29.9% YoY Diluted EPS
$-0.20
Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
Confident tone
KymTrah commercial performance and growth
Infectious disease pipeline (HIV / HBV)
Autoimmune programs
Revenue
$84.05M*
▲ 19.8% YoY Gross margin
99.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
Positive tone
Pipeline and clinical readouts
KIMMTRAK commercial performance
European reimbursement challenges
Revenue
$75.40M
▲ 26.2% YoY Diluted EPS
$-0.23
Gross margin
97.7%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-29
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Confident tone
PRAME franchise (F106C, PRISM-MEL301)
KIMMTRAK commercial performance
TEBE-AM Phase 2/3 trial in cutaneous melanoma
Revenue
$70.16M*
Gross margin
99.7%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Immunocore Holdings plc (IMCR) Q2 2023 Earnings Call Transcript
Revenue
$59.76M
Diluted EPS
$-0.35
Gross margin
99.4%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Immunocore Holdings plc (IMCR) Q4 2022 Earnings Call Transcript
No reported figures on file
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Immunocore Holdings plc (IMCR) Q2 2022 Earnings Call Transcript
No reported figures on file
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 webcasts
Key facts
CIK
1671927
CUSIP
45258D105
13F (30d)
150 filings
122 filers
Visit website
Investor relations